Please Wait.....
Report
Breast Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2017-2027 Segmented By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others), By (Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others), By Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others), By Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others), and By Region
Market Report I 2022-07-01 I 75 Pages I TechSci Research
The global breast cancer therapeutics market is expected to grow at an impressive CAGR in the forecast period, 2023-2027. Growing geriatric population susceptible to several chronic illnesses such as cancer is propelling the growth of the global breast cancer therapeutics market.
Breast cancer incidence and prevalence rates are expected to rise globally, boosting the global breast cancer therapeutics market. As a result, significant investment in research and development activities and technological advancements in cancer biology and pharmacology promote breast cancer therapeutics. Continuous advancements aid in the molecular understanding of breast cancer, and the introduction of novel solutions have reduced breast cancer mortality rates in recent years. Newly developed therapeutics effectively slow cancerous cell growth and proliferation, which is projected to boost the global breast cancer therapeutics market in the coming years.
The rising global prevalence of breast cancer and increasing demand for effective treatments for a large number of patients are expected to drive growth in the breast cancer therapeutics market. Breast cancer is one of the most common types of cancer worldwide, and improved diagnostic solutions are expected to drive market growth. Because of the numerous benefits of preventive care and early treatment, individuals sought diagnostic procedures, fueling the global breast cancer therapeutics market growth.
The global breast cancer therapeutics market is expected to grow as a result of government breast cancer screening initiatives and supportive programmes introduced by public organisations. According to the WHO report, early detection of breast cancer helps to reduce breast cancer mortality and increases the survival rate among patients with breast cancer. Many governments around the world encourage people to get screened for breast cancer, particularly women over the age of 50. Screening initiatives and public awareness campaigns are expected to increase the use of drugs for the effective treatment of breast cancer, propelling the global breast cancer therapeutics market growth over the forecast period.
The global breast cancer therapeutics market is segmented into type, end users, and regional distribution. Based on the type, the market is divided into chemotherapy, hormone therapy, immunotherapies, targeted therapy, and others. The targeted therapy is anticipated to register the highest growth in the global breast cancer treatment market, owing to emergence of personalized approach to improve clinical outcomes. Besides, developments in the treatment of metastatic hormone receptor-positive breast cancer have further accelerated the utilization of target-based therapies.
Key players operating in the global breast cancer treatment market are Novartis AG, Pfizer Inc., Eli Lilly & Company, Merck Co. & Inc., GlaxoSmithKline, Plc., AstraZeneca Plc., Bristol-Myers Squibb Company, Halozyme Inc., Eisai Co., Ltd., Fresenius Kabi AG, among others.
Years considered for this report:
Historical Years: 2017-2020
Base Year: 2021
Estimated Year: 2022
Forecast Period: 2023-2027
Objective of the Study:
- To analyze the historical growth in the market size of the global breast cancer therapeutics from 2017 to 2021.
- To estimate and forecast the market size of global breast cancer therapeutics market from 2023 to 2027 and growth rate until 2027.
- To classify and forecast the global breast cancer therapeutics market based on therapy, end user, region, and company.
- To identify the dominant region or segment in the global breast cancer therapeutics market.
- To identify drivers and challenges for the global breast cancer therapeutics market.
- To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in the global breast cancer therapeutics market.
- To identify and analyze the profiles of leading players operating in the global breast cancer therapeutics market.
- To identify key sustainable strategies adopted by market players in global breast cancer therapeutics market.
TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers across the country. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers who could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufacturers, distribution channels and presence of all major players across the country.
TechSci Research calculated the market size of the Global breast cancer therapeutics market using a top-down approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these products and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.
Key Target Audience:
- Market research and consulting firms
- Government bodies such as regulating authorities and policy makers
- Organizations, forums, and alliances
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as product manufacturers, suppliers and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.
Report Scope:
In this report, global breast cancer therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
- Breast Cancer Diagnostics Market, By Therapy:
o Chemotherapy
- Anthracyclines
- Taxanes
- Antimetabolites
- Others
o Hormone Therapy
- Selective Estrogen Receptor Modulators
- Aromatase Inhibitors
- Others
o Immunotherapies
o Targeted Therapy
- Monoclonal Antibodies
- Tyrosine Kinase Inhibitor
- Herceptin
- Others
o Others
- Breast Cancer Diagnostics Market, By End-User:
o Hospitals
o Specialty Clinics
o Ambulatory Surgical Centers
o Others
- Breast Cancer Diagnostics, By Region:
o North America
- United States
- Canada
- Mexico
o Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia
o Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
o South America
- Brazil
- Argentina
- Colombia
o Middle East & Africa
- Saudi Arabia
- South Africa
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in global breast cancer therapeutics market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. Product Therapy Overview
2. Research Methodology
3. Impact of COVID-19 on Global Breast Cancer Therapeutics Market
4. Voice of Customer
5. Executive Summary
6. Global Breast Cancer Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)
6.2.1.1. Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)
6.2.1.2. Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)
6.2.1.3. Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)
6.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
6.2.3. By Company (2021)
6.2.4. By Region
6.3. Product Market Map
7. North America Breast Cancer Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)
7.2.1.1. Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)
7.2.1.2. Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)
7.2.1.3. Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)
7.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
7.2.3. By Country
7.3. North America: Country Analysis
7.3.1. United States Breast Cancer Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Therapy
7.3.1.2.2. By End User
7.3.2. Mexico Breast Cancer Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Therapy
7.3.2.2.2. By End User
7.3.3. Canada Breast Cancer Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Therapy
7.3.3.2.2. By End User
8. Europe Breast Cancer Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)
8.2.1.1. Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)
8.2.1.2. Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)
8.2.1.3. Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)
8.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
8.2.3. By Country
8.3. Europe: Country Analysis
8.3.1. France Breast Cancer Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Therapy
8.3.1.2.2. By End User
8.3.2. Germany Breast Cancer Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Therapy
8.3.2.2.2. By End User
8.3.3. United Kingdom Breast Cancer Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Therapy
8.3.3.2.2. By End User
8.3.4. Italy Breast Cancer Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Therapy
8.3.4.2.2. By End User
8.3.5. Spain Breast Cancer Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Therapy
8.3.5.2.2. By End User
9. Asia-Pacific Breast Cancer Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)
9.2.1.1. Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)
9.2.1.2. Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)
9.2.1.3. Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)
9.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
9.2.3. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Breast Cancer Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Therapy
9.3.1.2.2. By End User
9.3.2. India Breast Cancer Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Therapy
9.3.2.2.2. By End User
9.3.3. Japan Breast Cancer Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Therapy
9.3.3.2.2. By End User
9.3.4. South Korea Breast Cancer Therapeutics Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Therapy
9.3.4.2.2. By End User
9.3.5. Australia Breast Cancer Therapeutics Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Therapy
9.3.5.2.2. By End User
10. South America Breast Cancer Therapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)
10.2.1.1. Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)
10.2.1.2. Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)
10.2.1.3. Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)
10.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Breast Cancer Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Therapy
10.3.1.2.2. By End User
10.3.2. Argentina Breast Cancer Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Therapy
10.3.2.2.2. By End User
10.3.3. Colombia Breast Cancer Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Therapy
10.3.3.2.2. By End User
11. Middle East and Africa Breast Cancer Therapeutics Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)
11.2.1.1. Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)
11.2.1.2. Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)
11.2.1.3. Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)
11.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
11.2.3. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Breast Cancer Therapeutics Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Therapy
11.3.1.2.2. By End User
11.3.2. Saudi Arabia Breast Cancer Therapeutics Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Therapy
11.3.2.2.2. By End User
11.3.3. UAE Breast Cancer Therapeutics Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Therapy
11.3.3.2.2. By End User
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
14. Competitive Landscape
14.1. Novartis AG
14.2. Pfizer Inc.
14.3. Eli Lilly & Company
14.4. Merck Co. & Inc.
14.5. GlaxoSmithKline, Plc.
14.6. AstraZeneca Plc.
14.7. Bristol-Myers Squibb Company
14.8. Halozyme Inc.
14.9. Eisai Co., Ltd.
14.10. Fresenius Kabi AG
15. Strategic Recommendations
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security